GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
GE HealthCare (GEHC) has scheduled the release of its first quarter 2025 financial results for Wednesday, April 30, 2025, before market opening. The company's management team will host a conference call and webcast at 8:30 AM Eastern Time / 7:30 AM Central Time on the same day.
The earnings release, accompanying financial materials, and webcast replay will be accessible through the company's Investor Relations website at investor.gehealthcare.com.
Cincinnati Children's and GE HealthCare (GEHC) have announced a groundbreaking strategic research collaboration to establish the first pediatric Care Innovation Hub nationwide. The partnership aims to advance pediatric medical imaging innovation across multiple modalities including MRI, CT, molecular imaging, and ultrasound.
The collaboration brings together Cincinnati Children's clinical expertise with GE HealthCare's medical technology capabilities to develop pediatric-focused imaging technologies. Key focus areas include: developing high-density MR coil arrays specifically sized for children, creating AI algorithms for ultrasound, evaluating new PET and SPECT imaging technologies, and optimizing CT workflows for pediatric patients.
This initiative represents a new model for combining resources and talent to accelerate innovation in pediatric imaging. The findings and technologies developed through this partnership are intended to benefit pediatric care providers globally, with the goal of improving clinical outcomes and patient care delivery.
GE HealthCare (Nasdaq: GEHC) has appointed Jeannette Bankes as president and CEO of Patient Care Solutions, effective May 1, 2025. Bankes, who brings three decades of global healthcare industry experience, joins from Alcon where she served as senior vice president and president of Global Franchises, overseeing product development and commercialization across surgical, vision care, and ocular health businesses.
The appointment was announced by Peter Arduini, president and CEO of GE HealthCare, who emphasized Bankes' proven leadership and extensive experience in publicly traded healthcare companies. She previously held senior leadership positions at Boston Scientific and Merck. Bankes will be based in Waukesha, Wisconsin, replacing Tom Westrick, who is retiring after 20+ years with the company. Westrick will remain until May 31, 2025, to ensure a smooth transition.
GE HealthCare (GEHC) has completed its acquisition of Sumitomo Chemical's 50% stake in Nihon Medi-Physics (NMP), giving it full ownership of the Japanese radiopharmaceutical company. NMP, which generated revenues of 28.2B JPY (~$183M) in 2023, specializes in developing and manufacturing radiopharmaceuticals for SPECT and PET molecular imaging procedures.
Kevin O'Neill, President & CEO of GE HealthCare's Pharmaceutical Diagnostics segment, will also become President of NMP. The company expects this transaction to be neutral to Adjusted EPS in year one and accretive thereafter. The acquisition positions NMP to enhance patient access to next-generation radiopharmaceuticals in Japan, which is projected to become a leader in the $7 billion molecular imaging global market.
GE HealthCare (GEHC) has unveiled the Revolution™ Vibe CT system, featuring Unlimited One-Beat Cardiac imaging technology. The system addresses the growing global cardiovascular disease (CVD) challenge, projected to cause over 23 million deaths by 2030.
The new CT system delivers consistent, high-quality cardiac images even in challenging cases like atrial fibrillation and heavily calcified coronaries. Key features include ECG-less Cardiac, TrueFidelity DL, SnapShot Freeze 2, and AI-powered Effortless Workflow solutions. Clinical evaluation showed the system's one-step decision tree workflow reduced exam time by 50% and saved four minutes of radiologists' time per study.
The Revolution Vibe enables facilities to expand cardiac CT capacity while improving operational efficiency. The system supports CCTA (Cardiac CT Angiography) as a first-line investigation tool for suspected coronary artery disease, aligning with NICE recommendations and recent Medicare reimbursement rate increases.
GE HealthCare Technologies (Nasdaq: GEHC) has announced its quarterly dividend payment for Q1 2025. The company's Board of Directors has declared a cash dividend of $0.035 per share of Common Stock. The dividend will be paid on May 15, 2025, to shareholders who are on record as of April 25, 2025.
GE HealthCare (GEHC) has announced the U.S. launch of Flyrcado™, a groundbreaking positron emission tomography (PET) myocardial perfusion imaging agent for coronary artery disease detection, at ACC 2025. The product has received traditional pass-through payment status from CMS, effective April 1st.
Flyrcado, FDA-approved in 2024, offers higher diagnostic efficacy compared to SPECT imaging and is particularly effective for challenging-to-diagnose patients. With its 109-minute half-life, it enables exercise stress testing with cardiac PET imaging.
The company is also showcasing several AI-powered innovations at ACC, including:
- Updated CASE™ system for cardiac stress testing
- CardIQ Suite for calcium scoring and cardiac CT angiography
- AltiX AI.i edition of Mac-Lab™, CardioLab™ and ComboLab™ for cardiac catheterization procedures
GE HealthCare (GEHC) has launched Invenia ABUS Premium, an advanced 3D ultrasound system featuring AI-driven technology for breast cancer screening. The system is specifically designed for patients with dense breasts, where approximately 71% of cancers occur and traditional mammograms may miss one-third of cases.
The new system includes Verisound AI and AI Assistant, offering up to 40% faster scanning speeds and improved image quality. Key features include Scan Quality Assessment, Auto Nipple Detection, and a novel Reverse Curve transducer for enhanced patient comfort. The system's AI tools assist in detecting and characterizing breast lesions, potentially reducing unnecessary biopsies.
According to studies, 40% of women globally and 70% of Asian women have dense breast tissue, making them 4-6 times more likely to receive a breast cancer diagnosis. The system will launch in key markets throughout 2025 and has received FDA Premarket Approval.
GE HealthCare (GEHC) has announced a significant collaboration with NVIDIA at GTC 2025 to develop autonomous X-ray and ultrasound solutions. The partnership aims to address healthcare challenges including staff shortages and increasing diagnostic demands, with 4.2 billion medical imaging examinations performed annually worldwide.
The collaboration leverages NVIDIA's Isaac for Healthcare platform, built on NVIDIA's computing infrastructure for physical AI, including Omniverse for robotic simulation. GE HealthCare plans to use NVIDIA's Cosmos platform for synthetic data generation and simulation to train autonomous devices before real-world deployment.
The initiative focuses on two key areas: transforming X-ray workflows by automating repetitive tasks and developing autonomous ultrasound systems to address the 90% of sonographers reporting work-related musculoskeletal disorders. This builds on their 16-year relationship and GE HealthCare's track record of 85 FDA AI-enabled device authorizations.
GE HealthCare (GEHC) has launched the AltiX AI.i edition of Mac-Lab, CardioLab, and ComboLab, enhancing cardiac catheterization and electrophysiology procedures. This advancement comes as cardiovascular disease affects over 500 million people globally, having nearly doubled in three decades.
The new solutions offer:
- Mac-Lab: Features diastolic pressure ratio algorithm and Cath Lab Command Center access
- CardioLab: Includes Prucka 3 digital amplifier for improved signal quality and Volta Interface for AI-powered atrial fibrillation assessment
- ComboLab: Integrates EP and hemodynamic recording in a single system
AltiX AI.i is currently available for order in the United States, with global markets launch planned later this year. The company will showcase these solutions at EHRA 2025 in Vienna and HRS 2025 in San Diego.